Celgene’s Revlimid Approved For Second-Line Multiple Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will begin shipping 15 mg and 25 mg tablets at the end of the first week of July following sNDA approval announced June 29.
You may also be interested in...
CHMP’s Revlimid Rebuff Will Have Limited Impact In EU Market
Analyst calls vote “more of a psychological setback” than anything, as drug already is approved on named-patient basis.
CHMP’s Revlimid Rebuff Will Have Limited Impact In EU Market
Analyst calls vote “more of a psychological setback” than anything, as drug already is approved on named-patient basis.
Celgene Phase III Revlimid Data Show Survival Advantage In Multiple Myeloma Patients
Trial also showed longest median time to disease progression, 11.3 months, reported in previously treated MM patients in a Phase III study.